Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA Recorded on September 25, 2025 Rahul Banerjee, MD, FACP Assistant Professor Fred Hutchinson Cancer Center Seattle, WA In this episode, Dr. Rahul Banerjee from Fred Hutchinson Cancer Center in Seattle, WA, discusses the evolving role of measurable residual disease (MRD) in hematologic malignancies. He explores what MRD is, how assays are used and interpreted, and its impact across the disease continuum. The conversation also covers MRD’s role in clinical trials, how to effectively explain MRD to patients, practical considerations for testing in community settings, and key education resources for both healthcare professionals and patients. Tune in today to gain practical insights you can apply in your daily practice! This episode is supported by Adaptive Biotechnologies Corporation and Allogene Therapeutics.